Transgene Biotek reported a widened net loss of ₹16.53 crore for the financial year ended March 31, 2026, compared to a net loss of ₹6.76 crore in the previous year. The loss was primarily driven by a surge in finance costs to ₹10.60 crore in FY26 from ₹2.43 crore in the prior year. Revenue from operations fell to ₹2.11 crore in FY26 from ₹2.61 crore in FY25, while total income dropped to ₹3.61 crore from ₹10.44 crore. The company's equity share capital remained constant at ₹757.70 lakh.

The Board of Directors approved the audited financial results for the fourth quarter and financial year ended March 31, 2026, at a meeting held on May 29, 2026. M/s. Vasavi & Co, Chartered Accountants, issued an Independent Auditors' Report with an unmodified opinion on both the standalone and consolidated financial results. The auditors confirmed that the results give a true and fair view of the company's financial position in conformity with Indian accounting standards.

Financial Performance

For the quarter ended March 31, 2026, the company reported a net loss of ₹4.57 crore, compared to a net loss of ₹7.13 crore in the same quarter of the previous year. Revenue from operations for the quarter stood at ₹0.55 crore, down from ₹0.77 crore in Q4 FY25. Total expenses for the quarter were ₹6.61 crore, a decrease from ₹8.33 crore in the corresponding prior period.

The basic and diluted earnings per share (EPS) for FY26 were reported at a loss of ₹0.22 per share, compared to a loss of ₹0.09 per share in FY25.

Standalone Financial Results

The following table summarizes the standalone financial performance for the year ended March 31, 2026:

Consolidated Financial Results

The consolidated financial results for the year ended March 31, 2026, mirrored the standalone figures, with a net loss of ₹16.53 crore on a total income of ₹3.61 crore. The consolidated results include the financials of Transgene Biotech HK Ltd, a subsidiary that has not been in operations for many years. The auditors noted that the subsidiary's books of accounts have not been audited recently, and the last available figures from 2015-16 are being carried forward for consolidation.

Asset and Liability Position

As of March 31, 2026, the company's total assets stood at ₹33.76 crore, a decrease from ₹34.20 crore in the previous year. Non-current assets were ₹32.75 crore, while current assets were ₹1.02 crore. Total equity and liabilities amounted to ₹33.76 crore, with equity showing a negative balance of ₹9.20 crore. Non-current liabilities were ₹29.82 crore, and current liabilities were ₹13.14 crore.

Cash and cash equivalents decreased to ₹0.61 crore as of March 31, 2026, from ₹2.84 crore in the prior year. The net cash flow from operating activities was negative at ₹0.11 lakh, compared to a positive flow of ₹11.96 lakh in FY25.

Transgene Biotek Limited has officially communicated to the Bombay Stock Exchange (BSE) that it does not meet the criteria to be classified as a "Large Corporate" under the Securities and Exchange Board of India (SEBI) regulations. The confirmation was made through a formal letter dated April 13, 2026, signed by the company's Chairman and Managing Director, Dr K Koteswara RAO.

Regulatory Compliance Confirmation

The company's declaration specifically references SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018, which pertains to fund raising by issuance of debt securities by large entities. Additionally, the communication cites BSE Circular No. LIST/COM/05/2019-20 dated April 11, 2019, which provides further guidance on the implementation of these regulations.

Large Corporate Classification Criteria

According to the company's statement, Transgene Biotek Limited does not fulfill the criteria specified in Para 2.2 of the aforementioned SEBI circular. This means the biotechnology company remains outside the regulatory framework that governs large corporate entities in terms of debt securities issuance and related compliance requirements.

Corporate Governance and Transparency

The proactive communication to the stock exchange demonstrates the company's commitment to maintaining transparency with regulatory authorities and ensuring proper classification under applicable securities regulations. This formal confirmation helps establish clear regulatory positioning for the company and its stakeholders.

The letter was submitted to the General Manager of the Bombay Stock Exchange Limited's Listing Compliance Department, ensuring that the exchange has updated records regarding the company's regulatory status for future reference and compliance monitoring.